Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 4,676 shares at $452.69 ($2.1M) on 2025-10-02, disclosed to the SEC on 2025-10-03.
Open-market sale of $2.1M ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $446.53 | 96 | $43K | 2.0% |
| 2 | $447.92 | 47 | $21K | 1.0% |
| 3 | $448.77 | 150 | $67K | 3.2% |
| 4 | $448.77 | 150 | $67K | 3.2% |
| 5 | $449.79 | 207 | $93K | 4.4% |
| 6 | $449.79 | 207 |
| $93K |
| 4.4% |
| 7 | $450.81 | 449 | $202K | 9.6% |
| 8 | $450.81 | 449 | $202K | 9.6% |
| 9 | $451.86 | 276 | $125K | 5.9% |
| 10 | $451.86 | 276 | $125K | 5.9% |
| 11 | $452.69 | 555 | $251K | 11.9% |
| 12 | $452.69 | 555 | $251K | 11.9% |
| 13 | $453.77 | 273 | $124K | 5.9% |
| 14 | $453.77 | 273 | $124K | 5.9% |
| 15 | $454.84 | 203 | $92K | 4.4% |
| 16 | $454.84 | 203 | $92K | 4.4% |
| 17 | $455.82 | 60 | $27K | 1.3% |
| 18 | $457.43 | 122 | $56K | 2.6% |
| 19 | $457.43 | 122 | $56K | 2.6% |
| 20 | $457.64 | 3 | $1K | 0.1% |
| Total | $452.15 avg | 4,676 | $2.1M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |